| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
1
Research Division, R & D Center, BML, Inc., 1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan.
2
Department of Cardiovascular Biochemistry, St.
Bartholomew’s & The Royal London School of Medicine & Dentistry,
Charterhouse Square, London EC1M 6BQ, United Kingdom.
a Author for correspondence. Fax 44-20-7882-6169; e-mail n.e.miller{at}mds.qmw.ac.uk
Background: Plasma phospholipid transfer protein (PLTP) plays a central role in the remodeling of HDLs. Reliable and accurate methods for assaying PLTP concentration are required.
Methods: A sandwich ELISA for PLTP has been developed, using two monoclonal antibodies against recombinant human PLTP (rhPLTP) expressed in Chinese hamster ovary cells. The ELISA allows for the quantification of PLTP in the range 0.625–15.0 ng/assay (1.2–30.0 mg/L). Intra- and interassay CVs were <3.0% and <4.2% respectively. The assay was used to quantify plasma PLTP concentrations in 132 Japanese subjects (75 males and 57 females).
Results: PLTP concentrations were 12.0 ± 3.0 mg/L (mean ± SD; range, 4.9–20.5 mg/L). No sex difference was observed. Plasma PLTP concentration was positively correlated with HDL-cholesterol (r = 0.72; P <0.001), apolipoprotein (apo) A-I (r = 0.62; P <0.001) and HDL2-cholesterol (r = 0.72; P <0.001), and was negatively correlated with triacylglycerol (r = -0.45; P <0.001). There was no correlation with plasma apo A-II. These results agree with other evidence that plasma PLTP is associated with large apo A-I-containing lipoproteins. There was no correlation (r = -0.01) between plasma PLTP and plasma phosphatidylcholine transfer activity (range, 3.5–10.5 µmol · mL-1 · h-1), suggesting that PLTP may exist in active and inactive forms.
Conclusion: This new ELISA will be of value for further studies of PLTP in health and disease.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  H. Samyn, M. Moerland, T. van Gent, R. van Haperen, J. Metso, F. Grosveld, M. Jauhiainen, A. van Tol, and R. de Crom Plasma phospholipid transfer activity is essential for increased atherogenesis in PLTP transgenic mice: a mutation-inactivation study J. Lipid Res., December 1, 2008; 49(12): 2504 - 2512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Dallinga-Thie, A. van Tol, H. Hattori, P. C.N. Rensen, E. J.G. Sijbrands, and for the Diabetes Atorvastatin Lipid Intervention ( Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein e? Diabetes, May 1, 2006; 55(5): 1491 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Siggins, M. Karkkainen, J. Tenhunen, J. Metso, E. Tahvanainen, V. M. Olkkonen, M. Jauhiainen, and C. Ehnholm Quantitation of the active and low-active forms of human plasma phospholipid transfer protein by ELISA J. Lipid Res., February 1, 2004; 45(2): 387 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kujiraoka, T. Iwasaki, M. Ishihara, M. Ito, M. Nagano, A. Kawaguchi, S. Takahashi, J. Ishi, M. Tsuji, T. Egashira, et al. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus J. Lipid Res., October 1, 2003; 44(10): 2006 - 2014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Siggins, M. Jauhiainen, V. M. Olkkonen, J. Tenhunen, and C. Ehnholm PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma J. Lipid Res., September 1, 2003; 44(9): 1698 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kujiraoka, M. N. Nanjee, T. Oka, M. Ito, M. Nagano, C. J. Cooke, S. Takahashi, W. L. Olszewski, J. S. Wong, I. P. Stepanova, et al. Effects of Intravenous Apolipoprotein A-I/Phosphatidylcholine Discs on LCAT, PLTP, and CETP in Plasma and Peripheral Lymph in Humans Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1653 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. A. M. Jonkers, A. H. M. Smelt, H. Hattori, L. M. Scheek, T. van Gent, F. H. A. F. de Man, A. van der Laarse, and A. van Tol Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy J. Lipid Res., August 1, 2003; 44(8): 1462 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lie, R. de Crom, T. van Gent, R. van Haperen, L. Scheek, I. Lankhuizen, and A. van Tol Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion J. Lipid Res., November 1, 2002; 43(11): 1875 - 1880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Oka, S. Yamashita, T. Kujiraoka, M. Ito, M. Nagano, Y. Sagehashi, T. Egashira, M. N. Nanjee, K.-i. Hirano, N. E. Miller, et al. Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia J. Lipid Res., August 1, 2002; 43(8): 1236 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Karkkainen, T. Oka, V. M. Olkkonen, J. Metso, H. Hattori, M. Jauhiainen, and C. Ehnholm Isolation and Partial Characterization of the Inactive and Active Forms of Human Plasma Phospholipid Transfer Protein (PLTP) J. Biol. Chem., May 3, 2002; 277(18): 15413 - 15418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Murdoch, G. Wolfbauer, H. Kennedy, S. M. Marcovina, M. C. Carr, and J. J. Albers Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement J. Lipid Res., February 1, 2002; 43(2): 281 - 289. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
